Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Theratechnologies News

    1,34 $ +3,88% +0,05 $
    In : 1,2575 € | 19.04.24 21:45:18 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3ERKM
    ISIN: CA88338H7040
    US-Symbol: THTX
    Typ: Aktie

    Theratechnologies News

    07.02.24 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Theratechnologies Inc. - THTX
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Theratechnologies Inc. - THTX PR Newswire
    30.01.24 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Theratechnologies Inc. - THTX
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Theratechnologies Inc. - THTX PR Newswire
    21.12.23 - PR Newswire
    Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
    Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement PR Newswire
    26.12.22 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theratechnologies Inc. - THTX
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theratechnologies Inc. - THTX PR Newswire
    27.04.22 - PR Newswire
    THERATECHNOLOGIES TO FOCUS ITS COMMERCIALIZATION ACTIVITIES ON THE NORTH AMERICAN TERRITORY
    THERATECHNOLOGIES TO FOCUS ITS COMMERCIALIZATION ACTIVITIES ON THE NORTH AMERICAN TERRITORY PR Newswire
    23.11.21 - PR Newswire
    Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended
    Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-​The-Market Facility to be Extended PR Newswire
    26.10.21 - GlobeNewswire
    Theratechnologies Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resistant HIV-1
    MONTREAL, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the ...
    30.09.20 - GlobeNewswire
    Theratechnologies to Present at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5
    MONTREAL, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the ...
    10.09.20 - PR Newswire
    Theratechnologies Announces Launch of Trogarzo® in Germany
    Theratechnologies Announces Launch of Trogarzo® in Germany PR Newswire
    10.09.20 - GlobeNewswire
    Theratechnologies Announces Launch of Trogarzo® in Germany
    First commercial launch in Europe
    02.03.20 - PR Newswire
    Change to Theratechnologies Management
    Change to Theratechnologies Management PR Newswire
    07.11.19 - GlobeNewswire
    Trogarzo® Remains Effective Close to a Decade After Treatment Initiation
    MONTREAL, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-​stage biopharmaceutical company, is ...
    27.09.19 - GlobeNewswire
    Europäische Kommission erteilt Zulassung für Trogarzo®
    MONTREAL, Kanada, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) freut sich bekannt zu geben, dass Trogarzo ® (Ibalizumab) ...
    26.09.19 - GlobeNewswire
    European Commission Approves Trogarzo®
    MONTREAL, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Trogarzo ® (ibalizumab) was approved today ...
    26.09.19 - PR Newswire
    Toronto Stock Exchange Introduces the TSX30
    Toronto Stock Exchange Introduces the TSX30 Canada NewsWire
    06.03.18 - PR Newswire
    Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1
    Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-​uiyk) Injection, the First HIV-1 Inhibitor and Long-​Acting Monoclonal Antibody for ...
    06.03.18 - PR Newswire
    Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1
    Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-​uiyk) Injection, the First HIV-1 Inhibitor and Long-​Acting Monoclonal Antibody for ...
    06.03.18 - PR Newswire
    Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1
    Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-​uiyk) Injection, the First HIV-1 Inhibitor and Long-​Acting Monoclonal Antibody for ...
    06.03.18 - PR Newswire
    IIROC Trade Resumption - TH
    IIROC Trade Resumption - TH Canada NewsWire
    06.03.18 - PR Newswire
    IIROC Trading Halt - TH
    IIROC Trading Halt - TH Canada NewsWire

    Newssuche

    Videos

    newspaper
    18.04.24
    Technical Trading: Gold mit weiterem Potenzial
    Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »